These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 21576524)
1. ACP journal club. Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatment. Douketis J Ann Intern Med; 2011 May; 154(10):JC5-06, JC5-07. PubMed ID: 21576524 [No Abstract] [Full Text] [Related]
2. ACP Journal Club. Enoxaparin plus idrabiotaparinux was noninferior to enoxaparin plus warfarin for recurrent VTE in acute PE. Dentali F Ann Intern Med; 2012 May; 156(10):JC5-4. PubMed ID: 22586022 [No Abstract] [Full Text] [Related]
4. ACP Journal Club. Outpatient treatment was noninferior to inpatient treatment for preventing recurrent VTE in low-risk patients with acute PE. Bates SM; Guyatt GH Ann Intern Med; 2011 Oct; 155(8):JC4-2. PubMed ID: 22007061 [No Abstract] [Full Text] [Related]
5. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Cohen AT; Dobromirski M Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186 [TBL] [Abstract][Full Text] [Related]
6. ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. Witt DM Ann Intern Med; 2012 Aug; 157(4):JC2-6. PubMed ID: 22910960 [No Abstract] [Full Text] [Related]
7. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107 [TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery. Duggan ST Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729 [TBL] [Abstract][Full Text] [Related]
10. ACP journal club. Apixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacement. Douketis J Ann Intern Med; 2011 May; 154(10):JC5-07, JC5-06. PubMed ID: 21576525 [No Abstract] [Full Text] [Related]
11. ACP Journal Club. Extended-duration enoxaparin reduced VTE but increased major bleeding in patients with acute medical illness. Gallus A Ann Intern Med; 2010 Nov; 153(10):JC5-8. PubMed ID: 21079215 [No Abstract] [Full Text] [Related]
12. ACP Journal Club. Short-term was less effective than long-term flecainide for preventing recurrent AF after cardioversion. Wyse DG Ann Intern Med; 2012 Sep; 157(6):JC3-9. PubMed ID: 22986401 [No Abstract] [Full Text] [Related]
13. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028 [TBL] [Abstract][Full Text] [Related]
14. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. Cheng JW; Vu H Clin Ther; 2012 Apr; 34(4):766-87. PubMed ID: 22444784 [TBL] [Abstract][Full Text] [Related]
15. ACP Journal Club. Surgical masks were noninferior to N95 respirators for preventing influenza in health care providers. Radonovich LJ; Bender BS Ann Intern Med; 2010 Mar; 152(6):JC3-2. PubMed ID: 20231556 [No Abstract] [Full Text] [Related]
16. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Turpie AG; Lassen MR; Eriksson BI; Gent M; Berkowitz SD; Misselwitz F; Bandel TJ; Homering M; Westermeier T; Kakkar AK Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019 [TBL] [Abstract][Full Text] [Related]
17. ACP Journal Club. Review: Dabigatran increases MI and reduces mortality compared with warfarin, enoxaparin, or placebo. Cairns J Ann Intern Med; 2012 Jun; 156(12):JC6-11. PubMed ID: 22711112 [No Abstract] [Full Text] [Related]
18. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948 [TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG; N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812 [TBL] [Abstract][Full Text] [Related]
20. Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications. Rosenberg DJ; Ansell J Evid Based Med; 2011 Oct; 16(5):139-40. PubMed ID: 21460399 [No Abstract] [Full Text] [Related] [Next] [New Search]